CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.160
-0.050 (-2.26%)
Mar 10, 2025, 11:20 AM EST - Market open
CervoMed Stock Forecast
CRVO's stock price has decreased by -86.95% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CervoMed stock have an average target of 33, with a low estimate of 10 and a high estimate of 63. The average target predicts an increase of 1,427.78% from the current stock price of 2.16.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CervoMed stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Hold → Strong Buy Upgrades $10 | Hold → Strong Buy | Upgrades | $10 | +362.96% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 17, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $65 → $12 | Strong Buy | Maintains | $65 → $12 | +455.56% | Dec 11, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 10, 2024 |
Financial Forecast
Revenue This Year
9.59M
from 7.14M
Increased by 34.17%
Revenue Next Year
5.39M
from 9.59M
Decreased by -43.76%
EPS This Year
-1.84
from -0.82
EPS Next Year
-1.35
from -1.84
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 13.0M | 12.5M | n/a | |||
| Avg | 9.6M | 5.4M | n/a | |||
| Low | 7.9M | 1.4M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 82.2% | 30.3% | - | |||
| Avg | 34.2% | -43.8% | - | |||
| Low | 11.1% | -85.7% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.38 | -0.08 | -1.33 | |||
| Avg | -1.84 | -1.35 | -2.23 | |||
| Low | -2.08 | -2.15 | -2.99 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.